FI873672A - Kompositioner innehaollande l-3,4-dihydroxifenylalanin. - Google Patents

Kompositioner innehaollande l-3,4-dihydroxifenylalanin. Download PDF

Info

Publication number
FI873672A
FI873672A FI873672A FI873672A FI873672A FI 873672 A FI873672 A FI 873672A FI 873672 A FI873672 A FI 873672A FI 873672 A FI873672 A FI 873672A FI 873672 A FI873672 A FI 873672A
Authority
FI
Finland
Prior art keywords
weight during
dihydroxiphenylalan
dopa
release
accordance
Prior art date
Application number
FI873672A
Other languages
English (en)
Other versions
FI873672A0 (fi
FI86689C (fi
FI86689B (fi
Inventor
Curt Henry Appelgren
Eva Christina Eskilsson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Publication of FI873672A0 publication Critical patent/FI873672A0/fi
Publication of FI873672A publication Critical patent/FI873672A/fi
Application granted granted Critical
Publication of FI86689B publication Critical patent/FI86689B/fi
Publication of FI86689C publication Critical patent/FI86689C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
FI873672A 1986-08-26 1987-08-25 Foerfarande foer framstaellning av en multipel-unit-doskomposition, som innehaoller l-dopa som farmaceutiskt aktiv substans FI86689C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8603582 1986-08-26
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (4)

Publication Number Publication Date
FI873672A0 FI873672A0 (fi) 1987-08-25
FI873672A true FI873672A (fi) 1988-02-27
FI86689B FI86689B (fi) 1992-06-30
FI86689C FI86689C (fi) 1992-10-12

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
FI873672A FI86689C (fi) 1986-08-26 1987-08-25 Foerfarande foer framstaellning av en multipel-unit-doskomposition, som innehaoller l-dopa som farmaceutiskt aktiv substans

Country Status (15)

Country Link
US (1) US4981695A (fi)
EP (1) EP0260236B1 (fi)
JP (1) JPH0662405B2 (fi)
AT (1) ATE58292T1 (fi)
CA (1) CA1298198C (fi)
DD (1) DD286107A5 (fi)
DE (1) DE3766200D1 (fi)
DK (1) DK442287A (fi)
ES (1) ES2036221T3 (fi)
FI (1) FI86689C (fi)
HU (1) HU197211B (fi)
MX (1) MX172918B (fi)
NO (1) NO176549C (fi)
PT (1) PT85591B (fi)
SE (1) SE460947B (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
SI1408964T1 (sl) * 2001-07-26 2007-06-30 Merck Patent Gmbh Uporaba 2- 5-(4-fluorofenil)-3-piridilmetil-aminometil -kromana in njegovih fizioloĺ ko sprejemljivih soli
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
KR20060109922A (ko) * 2003-10-31 2006-10-23 알자 코포레이션 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
JP2007517776A (ja) * 2003-12-09 2007-07-05 スフェリックス， インコーポレイテッド カテコール官能基を有する生体接着性ポリマー
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
WO2007084383A2 (en) * 2006-01-13 2007-07-26 University Of South Carolina Method and composition for the treatment of parkinson's disease
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (fi) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
ATE58292T1 (de) 1990-11-15
DD286107A5 (de) 1991-01-17
NO176549B (no) 1995-01-16
JPH0662405B2 (ja) 1994-08-17
JPS63139128A (ja) 1988-06-10
ES2036221T3 (es) 1993-05-16
HU197211B (en) 1989-03-28
CA1298198C (en) 1992-03-31
SE8603582L (sv) 1988-02-27
DK442287A (da) 1988-02-27
EP0260236B1 (en) 1990-11-14
NO873589D0 (no) 1987-08-25
FI873672A0 (fi) 1987-08-25
SE8603582D0 (sv) 1986-08-26
US4981695A (en) 1991-01-01
DE3766200D1 (de) 1990-12-20
NO873589L (no) 1988-02-29
FI86689C (fi) 1992-10-12
EP0260236A1 (en) 1988-03-16
MX172918B (es) 1994-01-21
NO176549C (no) 1995-04-26
PT85591A (en) 1987-09-01
PT85591B (pt) 1990-05-31
FI86689B (fi) 1992-06-30
SE460947B (sv) 1989-12-11
DK442287D0 (da) 1987-08-25
HUT44438A (en) 1988-03-28

Similar Documents

Publication Publication Date Title
FI873672A0 (fi) Kompositioner innehaollande l-3,4-dihydroxifenylalanin.
YU174490A (sh) Novi estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje i primena tih jedinjenja
FI925100A0 (fi) Substituerade bifenylpyridoner
CA2054358A1 (en) High acid nutritional formulations
SE8502950L (sv) Ny galenisk retardform
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DK0414007T3 (da) Hidtil ukendt arginindeiminase, dens fremstillingsmetode og et anti-cancermiddel indeholdende dette enzym som en effektiv ingrediens
SE8700137L (sv) Diuretisk komposition
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
SE8803583L (sv) Farmaceutisk komposition
DE3764235D1 (de) Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
JPS56148291A (en) Stabilizing agent for enzyme
HK50094A (en) Skin detergent composition
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
SE8701077L (sv) Farmaceutisk beredning
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
ATE41602T1 (de) Parenterale zusammensetzung.

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: ASTA MEDICA AKTIENGESELLSCHAFT